These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22312942)

  • 1. Unpredicted adverse reaction to omalizumab.
    Jandus P; Hausmann O; Haeberli G; Gentinetta T; Mueller U; Helbling A
    J Investig Allergol Clin Immunol; 2011; 21(7):563-6. PubMed ID: 22312942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.
    González de Olano D; Alvarez-Twose I; Esteban-López MI; Sánchez-Muñoz L; de Durana MD; Vega A; García-Montero A; González-Mancebo E; Belver T; Herrero-Gil MD; Fernández-Rivas M; Orfao A; de la Hoz B; Castells MC; Escribano L
    J Allergy Clin Immunol; 2008 Feb; 121(2):519-26. PubMed ID: 18177694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mastocytosis and insect venom allergy.
    Bonadonna P; Zanotti R; Müller U
    Curr Opin Allergy Clin Immunol; 2010 Aug; 10(4):347-53. PubMed ID: 20485157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report.
    Sokol KC; Ghazi A; Kelly BC; Grant JA
    J Allergy Clin Immunol Pract; 2014; 2(3):266-70. PubMed ID: 24811015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting.
    Palgan K; Bartuzi Z; Gotz-Zbikowska M
    Int J Immunopathol Pharmacol; 2014; 27(1):109-12. PubMed ID: 24674685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab and hypersensitivity reactions.
    Shankar T; Petrov AA
    Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):19-24. PubMed ID: 23242113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab.
    Galera C; Soohun N; Zankar N; Caimmi S; Gallen C; Demoly P
    J Investig Allergol Clin Immunol; 2009; 19(3):225-9. PubMed ID: 19610266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
    Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B;
    J Allergy Clin Immunol; 2010 Jul; 126(1):105-11.e5. PubMed ID: 20542320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations.
    Bonadonna P; Gonzalez-de-Olano D; Zanotti R; Riccio A; De Ferrari L; Lombardo C; Rogkakou A; Escribano L; Alvarez-Twose I; Matito A; Vega A; Passalacqua G
    J Allergy Clin Immunol Pract; 2013; 1(5):474-8. PubMed ID: 24565619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose.
    Stretz E; Oppel EM; Räwer HC; Chatelain R; Mastnik S; Przybilla B; Ruëff F
    Clin Exp Allergy; 2017 Dec; 47(12):1631-1639. PubMed ID: 28802075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy.
    White KM; England RW
    Ann Allergy Asthma Immunol; 2008 Oct; 101(4):426-30. PubMed ID: 18939733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hymenoptera venom immunotherapy and field stings.
    Lang R; Hawranek T
    J Investig Allergol Clin Immunol; 2006; 16(4):224-31. PubMed ID: 16889279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a short pretreatment with omalizumab in children with anaphylaxis to hymenoptera venom immunotherapy: A report of three cases.
    Droitcourt C; Ponvert C; Dupuy A; Scheinmann P; Abou-Taam R; de Blic J; Lezmi G
    Allergol Int; 2019 Apr; 68(2):268-269. PubMed ID: 30342888
    [No Abstract]   [Full Text] [Related]  

  • 15. Basophil sensitivity in patients not responding to venom immunotherapy.
    Peternelj A; Silar M; Erzen R; Kosnik M; Korosec P
    Int Arch Allergy Immunol; 2008; 146(3):248-54. PubMed ID: 18270492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of basophil activation in mastocytosis with Hymenoptera venom anaphylaxis.
    González-de-Olano D; Alvarez-Twose I; Morgado JM; Esteban López MI; Vega Castro A; Díaz de Durana MD; Sánchez-Muñoz L; Matito A; de la Hoz Caballer B; Sanz ML; Orfao A; Escribano L
    Cytometry B Clin Cytom; 2011 May; 80(3):167-75. PubMed ID: 21520404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of ultra-rush protocols for hymenoptera venom immunotherapy in systemic mastocytosis.
    Gruzelle V; Ramassamy M; Bulai Lidiveanu C; Didier A; Mailhol C; Guilleminault L
    Allergy; 2018 Nov; 73(11):2260-2263. PubMed ID: 29984458
    [No Abstract]   [Full Text] [Related]  

  • 18. Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis.
    Gülsen A; Ruëff F; Jappe U
    Allergol Select; 2021; 5():128-132. PubMed ID: 33733040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hymenoptera venom allergy.
    Ebo DG
    Verh K Acad Geneeskd Belg; 2007; 69(4):213-30. PubMed ID: 17821959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mastocytosis and Hymenoptera venom allergy.
    Ruëff F; Placzek M; Przybilla B
    Curr Opin Allergy Clin Immunol; 2006 Aug; 6(4):284-8. PubMed ID: 16825870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.